Pfizer Publish New Analysis Showing Long Term Therapy Slowed Progression of Rare Neurodegenerative Disease

Pfizer Inc. announced the recent publication of a post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5 and a half years, showed that treatment with VYNDAQEL initiated during the

Continue Reading